Dataset from A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients With COVID-19

The primary objectives are:Pooled Phase 3 (Cohort 1) and Phase 2 (Cohort 1A)* To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in reducing viral load of SARS-CoV-2* To evaluate the clinical efficacy of REGN10933+REGN10987 compared to placebo, as measured by death or mechanical ventilationPhase 1/2 (Cohort 1)* To exclude futility of REGN10933+REGN10987 compared to placebo, as measured by death or mechanical ventilation* To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo